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retrospective cohort study. The study took place in one centre. In the retrospective study, 38% of patients were lost to follow-up, the reason not being specified, although it appears to have been due to the availability of data. The duration of follow-up was not reported.
Analysis of effectiveness
In the prospective study, all the patients included in the study were accounted for in the analysis. The primary health outcomes used in the prospective study were the cell viability, cell recovery and engraftment success. Cell recovery was measured in percentage recovery of nucleated cells (NC) and percentage recovery of CFU-GM cells. Engraftment success was measured in days for absolute granulocyte count (AGC) to be greater than 500/microl and days for the patients' platelet count to be greater than 20,000/microl. In the retrospective study data were presented for 78 patients. The primary health outcome used in the retrospective study was engraftment success measured as in the prospective study but stratified by CD34+ cell dose.
Effectiveness results
In the prospective study, 100% cell viability was achieved. 99.5% (range: 88% -100%) of nucleated cells were recovered and 98% (range: 61% -100%) of CFU-GM cells were recovered. The median time for patients to reach an AGC level greater than 500/microl was 11 days; the median time for patients to reach a platelet count greater than 20,000/microl was 12 days.
In the retrospective study, the median time for patients to reach an AGC level greater than 500/microl was 10 days (range: 9 -11); the median time for patients to reach a platelet count greater than 20,000/microl was 12 days (range: 7 -70). All engraftments were successful.
Clinical conclusions
PBSC products were not adversely affected by overnight storage and patient recovery was not affected by using those products.
Modelling
No modelling was conducted.
Measure of benefits used in the economic analysis
The authors stated that the use of overnight storage of PBSC products had no effect on patient outcome, therefore the economic analysis was based on cost differences only (cost-minimisation).
Direct costs
The costing was only performed on the retrospective study. Some quantities of resources were specified separately from costs (staff time for processing PBSC products). The perspective adopted was that of the stem-cell laboratory. Direct costs included were staff time, materials, and disposables. The method used to estimate quantities and unit costs was not reported. Discounting was not conducted as the time frame of the study was less than a year. The price year was not reported.
